|
Press Releases |
|
 |
|
Wednesday, April 14, 2021 |
|
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting |
Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401). more info >> |
|
エーザイ、米国神経学会年次総会にて神経領域の開発品・製品に関する最新データを発表 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、2021年4月17日から22日までバーチャルで開催される「米国神経学会(American Academy of Neurology)年次総会:AAN2021」において、抗アミロイドB(AB)プロトフィブリル抗体lecanemab(開発品コード:BAN2401)、デュアルオレキシン受容体拮抗剤レンボレキサント(製品名「デエビゴ(R)」、海外製品名「Dayvigo(R)」)および抗てんかん剤ペランパネル(製品名「フィコンパ(R)」、海外製品名「Fycompa(R)」)に関する最新データを発表しますのでお知らせします。 more info >> |
|
Monday, April 12, 2021 |
|
エーザイ、リンパ系フィラリア症の制圧活動に関するアニメーション動画がInternational Society for Neglected Tropical Diseasesフェスティバルアワード2021で「アニメーション賞」を受賞 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、リンパ系フィラリア症(LF)の制圧活動をテーマとして当社が制作したアニメーション動画「Leave No One Behind―顧みられない人々の病気―」が、International Society for Neglected Tropical Diseases (ISNTD)フェスティバルアワード 2021 の「アニメーション賞」を受賞したことをお知らせします。 more info >> |
|
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021 |
Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021. more info >> |
|
Wednesday, March 31, 2021 |
|
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries |
KYORIN Pharmaceutical Co., Ltd., a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei. more info >> |
|
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan |
Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., (known as MSD outside the United States and Canada) announced today that Eisai has submitted an application in Japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, LENVIMA. more info >> |
|
Tuesday, March 30, 2021 |
|
Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab |
Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has confirmed it has accepted for review applications for the use of its in-house discovered multiple receptor tyrosine kinase inhibitor, lenvatinib mesylate, in combination with anti-PD-1 therapy pembrolizumab. more info >> |
|
エーザイ、抗がん剤レンバチニブについてペムブロリズマブとの併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る2つの適応追加申請が欧州医薬品庁により受理 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)は、このたび、自社創製の抗がん剤レンバチニブメシル酸塩(製品名:「レンビマ(R)」、「Kisplyx(R)」、以下 レンバチニブ)について、Merck & Co., Inc. Kenilworth, N.J., U.S.A.(北米以外ではMSD)の抗PD-1抗体ペムブロリズマブ(製品名:「キイトルーダ(R)」、以下 ペムブロリズマブ)との併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る適応追加の申請をそれぞれ行い、欧州医薬品庁によって受理されましたのでお知らせします。 more info >> |
|
Friday, March 26, 2021 |
|
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 |
Eisai Co., Ltd. has announced that drug discovery research conducted on perampanel, the AMPA-type glutamate receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2021 by the PSJ. more info >> |
|
Tuesday, March 23, 2021 |
|
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan |
Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
May 16, 2025 17:21 JST
|
|
|
Premiere of New bZ Woodland BEV Focused on Driving Performance and Spaciousness in North America
May 16, 2025 16:35 JST
|
|
|
Mitsubishi Heavy Industries Activates New Driving Force for Data Center Business in the United States
May 16, 2025 15:43 JST
|
|
|
PCG Powers Hong Kong's Mega-Event Economy and Participates in InnoEX 2025
May 16, 2025 13:23 HKT/SGT
|
|
|
交易寶助力香港盛事經濟及亮相InnoEX 2025
May 16, 2025 13:08 HKT/SGT
|
|
|
交易宝助力香港盛事经济及亮相InnoEX 2025
May 16, 2025 12:40 HKT/SGT
|
|
|
TruMerit 讚揚世界衛生組織發布《世界護理現況報告》
May 16, 2025 11:30 HKT/SGT
|
|
|
Spiritual Business Guide 'Zen and Stilettos' Sells 100,000 Copies, Enters Publisher's Top-10
May 16, 2025 08:00: JST
|
|
|
Spiritual Business Guide 'Zen and Stilettos' Sells 100,000 Copies, Enters Publisher's Top-10
May 16, 2025 07:00 HKT/SGT
|
|
|
TruMerit Hails Release of WHO's State of the World's Nursing Report
May 16, 2025 07:00 HKT/SGT
|
|
|
Euro Manganese Announces Results of Annual General and Special Meeting
May 16, 2025 06:29 HKT/SGT
|
|
|
MHI Thermal Systems Receives JSRAE Technology Award
May 15, 2025 20:08 JST
|
|
|
全球運動品牌 U.S. Polo Assn. 在阿根廷推出男裝系列
May 15, 2025 19:00 HKT/SGT
|
|
|
Global Sports Brand U.S. Polo Assn. Launches Menswear in Argentina
May 15, 2025 19:00 HKT/SGT
|
|
|
全球运动品牌 U.S. Polo Assn. 在阿根廷推出男装系列
May 15, 2025 19:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|